Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
et al., European Respiratory Journal,
RCT 160 hospitalized patients in Brazil, showing no significant difference in outcomes with convalescent plasma.
risk of death, 38.5% higher, RR 1.38, p = 0.42, treatment 18 of 80 (22.5%), control 13 of 80 (16.2%), day 28.
risk of death, 100% higher, RR 2.00, p = 0.28, treatment 10 of 80 (12.5%), control 5 of 80 (6.2%), day 14.
risk of no improvement, 10.7% higher, RR 1.11, p = 0.74, treatment 31 of 80 (38.8%), control 28 of 80 (35.0%), day 28.
hospitalization time, 66.7% higher, relative time 1.67, p = 0.87, treatment 80, control 80.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sekine et al., 8 Jul 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 28 authors, study period 15 July, 2020 - 10 December, 2020, average treatment delay 10.0 days, trial NCT04547660 (history)
Abstract: EUROPEAN RESPIRATORY JOURNAL
ORIGINAL RESEARCH ARTICLE
L. SEKINE ET AL.
Convalescent plasma for COVID-19 in hospitalised patients: an
open-label, randomised clinical trial
Leo Sekine 1,2, Beatriz Arns3, Bruna R. Fabro3, Murillo M. Cipolatt3, Rafael R.G. Machado 4,
Edison L. Durigon4,5, Edino Parolo6, José Augusto S. Pellegrini6, Marina V. Viana6, Patrícia Schwarz6,
Thiago C. Lisboa6, José Miguel S. Dora 7,8, Julia P. Portich9, Alessandra A. Paz9, Lucia Silla9,
Almeri M. Balsan1, Felipe da-Silva Schirmer1, Juliana P.M. Franz1, Luciana M. da-Silveira1,
Raquel C. Breunig1, Viviana Petersen1, Monalisa Sosnoski1, Nanci F. Mesquita1,
Fabiana Caroline Z. Volpato10,11, Daniel Sganzerla12, Maicon Falavigna12, Regis G. Rosa13 and
Alexandre P. Zavascki 3,8 on behalf of PLACOVID Study Group14
Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 2Medical Sciences Post-Graduate Program,
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 3Infectious Diseases Service, Hospital de Clínicas de Porto Alegre,
Porto Alegre, Brazil. 4Dept of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. 5Scientific
Platform Pasteur USP, São Paulo, Brazil. 6Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 7Internal
Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 8Dept of Internal Medicine, Universidade federal do Rio
Grande do Sul, Porto Alegre, Brazil. 9Clinical Hematology and Bone Marrow Transplantation Service, Hospital de Clínicas de Porto
Alegre, Porto Alegre, Brazil. 10Laboratório de Diagnóstico de SARS-CoV-2, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 12Research
Projects Office, Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil. 13Intensive Care Service, Hospital Moinhos de Vento, Porto
Alegre, Brazil. 14The members of the PLACOVID Study Group are listed in the acknowledgements section.
Corresponding author: Alexandre P. Zavascki (email@example.com)
Shareable abstract (@ERSpublications)
In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus
standard of care compared to standard of care did not result in higher proportion of clinical
improvement on day 28 in patients with severe COVID-19 https://bit.ly/2TXuB6S
Cite this article as: Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised
patients: an open-label, randomised clinical trial. Eur Respir J 2022; 59: 2101471 [DOI: 10.1183/
Copyright ©The authors 2022.
This version is distributed under
the terms of the Creative
Non-Commercial Licence 4.0.
For commercial reproduction
rights and permissions contact
This article has an editorial
Received: 30 April 2021
Accepted: 16 June 2021
Background The effects of convalescent plasma (CP) therapy in hospitalised patients with coronavirus
disease 2019 (COVID-19) remain uncertain. This study investigates the effect of CP on clinical
improvement in these patients.
Methods This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical
trial. Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.